A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.
Katharina HanselA ZangrilliL BianchiKetty PerisAndrea ChiricozziA OffidaniDiotallevi FedericoMaria-Concetta FargnoliMaria EspositoP AmerioGiulio GualdiL BianchiLuca StingeniPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)